To investigate the effects of exercise in combination with a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, or placebo for the treatment of type 2 diabetes.
| INTRODUCTION
Physical activity is one of the three cornerstone recommendations (along with diet and medication) in the treatment of type 2 diabetes.
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Exercise training improves aerobic capacity and muscular strength and is often associated with fat loss and increased muscle mass. Furthermore, exercise training has a beneficial effect on insulin-mediated glucose uptake and is associated with increased glucose transporter 4 (GLUT4) expression and improved insulin signalling in skeletal muscle. 6, 7 Despite several studies reporting significant reductions in glycated haemoglobin (HbA1c) of 0.4% to 0.6% after increasing the level of physical activity, it is often not sufficient to normalize glycaemic control in patients with type 2 diabetes. 2, 8, 9 Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L cells located in the distal jejunum and ileum in response to meal ingestion.
GLP-1 is known mainly for its glucose-lowering and satiety-promoting effects. 10 Since 2006, GLP-1 receptor agonists (GLP-1RAs) have been used for the treatment of patients with type 2 diabetes. 11 Liraglutide is a once-daily administered GLP-1RA with beneficial effects on HbA1c levels, body weight and body composition in obese dysregulated patients with type 2 diabetes. 11 Nevertheless, a substantial proportion of GLP-1RA-treated patients do not reach glycaemic targets.
Exercise and GLP-1RAs have each been used for the treatment of patients with type 2 diabetes for several years; however, the combination of the two has, to our knowledge, never been evaluated in prospective trials before. We hypothesized that exercise training combined with GLP-1RA treatment would result in clinically relevant improvements in HbA1c and a range of other health-related variables, in obese, sedentary and dysregulated patients with established type 2 diabetes.
| METHODS

| Study design and endpoints
The study was a 16-week, randomized, double-blind, placebocontrolled study conducted at the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark. The study was conducted in accordance with the international Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The study was designed and conducted by the authors, and the authors vouch for the data and analyses, as well as the fidelity of this report to the study protocol. The study was an investigatorinitiated study, sponsored by Novo Nordisk, but Novo Nordisk had no role in the study design, data analysis or reporting of results. The primary endpoint was change in HbA1c (from baseline until end of study (16 weeks) were examined in the fasting state at baseline and at the end of the study with blood samples, blood pressure, resting heart rate, dual-energy X-ray absorptiometry scan and physical fitness test. End of study examinations were performed after the last liraglutide or placebo dose was given, the evening before and 42 to 75 hours after the last bout of exercise.
| Experimental procedures
A dual-energy X-ray absorptiometry scan (DPX-IQ Lunar, General Elec- Monark, Vansbro, Sweden). The workload was increased until a heart rate of 110 to 120 beats/min was achieved. At steady-state heart rate, oxygen uptake was measured (MasterScreen CPX system; Intramedic, Gentofte, Denmark). The workload was then increased to achieve a heart rate of 140 to 160 beats/min and oxygen uptake at steady state was measured again. The duration of the test was 10 to 12 minutes.
VO 2max was estimated from the measurements of VO 2 during the two-point step test and an estimation of maximum heart rate. 12 Resting heart rate and blood pressure were measured on the left arm after the patients had rested for 10 minutes. A health-related questionnaire, the Short-Form-36 Health Survey, was used to evaluate changes in QoL. 
| Calculations and statistical methods
Steady-state insulin resistance (HOMA-IR) and β-cell function (HOMA-β) were estimated using the HOMA2 calculator. 18 The statistical analyses were performed using STATA 12. and the baseline value as the independent variable. P values of <.05
were considered to indicate statistical significance. The statistical analyses were performed by P.M. and M.T.J. 
| Study registration
| RESULTS
From December 2011 to March 2013, a total of 34 patients were enrolled in the study, of whom 33 completed the full study. One patient was excluded because of lack of exercise compliance. Patient characteristics were similar in the two groups (Table 1) . Medical treatment was similar in the groups and remained unchanged during the study. Besides metformin, patients received no medication known to interfere with glucose metabolism.
| Glycated haemoglobin
Patients receiving exercise plus liraglutide experienced pronounced reductions in HbA1c, whereas no significant change was observed in the exercise plus placebo group (Table 2, Figure 2A ). In the exercise plus liraglutide group, 77% of patients obtained an HbA1c <7%
(53 mmol/mol) and 53% normalized their HbA1c concentration (<6.0% [42 mmol/mol]). In the exercise plus placebo group, the corresponding values were 25% and 6%, respectively ( Figure 2F ).
| Body weight and body composition
The mean (range) body weight was reduced by 3.4 (−8.5 kg to +2. 3) kg in patients treated with exercise plus liraglutide, whereas it remained unchanged with exercise alone (−1.6 [−9.3 to +2.8] kg; Figure 2C ). A significant reduction in body fat (%) was observed in both groups (Table 2 , Figure 2D ). Furthermore, gynoid and android fat (%) decreased significantly in both groups, with no difference between the groups. Lean body mass was unchanged from baseline in both groups ( Table 2) . Data from the simple questionnaire inquiring about the frequency and composition of the daily food intake before, midway and at the end of the study showed little or no change in food intake between the groups over 16 weeks.
| Exercise compliance and physical fitness
Overall exercise compliance was 89% AE 4%, equal to~2 hours and 41 min/wk during the 16-week intervention period. During spinning sessions, the mean intensity was 77% AE 2% of estimated maximum heart rate, with no difference between the groups. VO 2max increased significantly, by~17% in both groups, after 16 weeks ( Figure 2E ).
| FPG, insulin, C-peptide and HOMA-IR/β
A significant effect on FPG was seen with exercise plus liraglutide, whereas exercise plus placebo had no effect on FPG level ( Figure 2B ).
No changes were observed in fasting levels of insulin and C-peptide, respectively, in any of the groups. The estimated HOMA-IR and estimated steady-state β-cell function, HOMA-β, were both significantly improved with exercise plus liraglutide, whereas no changes were observed with exercise plus placebo (Table 3) .
| Lipids, liver enzyme, glucagon, GLP-1 and GIP concentrations
Lipids were unchanged after the interventions in both groups (Tables 2 and 3 ). Alanine transaminase decreased in both groups, whereas aspartate transaminase remained unchanged. No changes in fasting glucagon, GLP-1 or GIP were observed (Table 3 ).
| Blood pressure and heart rate
A significant reduction in systolic blood pressure was found in the exercise plus liraglutide group. No changes were seen in diastolic blood pressure or heart rate ( Table 2) .
| Health-related QoL
The health-related QoL summary score was significantly improved in the general health component and the physical function component in both groups without differences between the groups in any of the components (data not shown). Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; VO 2max , maximum oxygen uptake.
Data are presented as mean AE standard deviation.
| Adverse events
Gastrointestinal side effects (mild/moderate and transient nausea, QoL were observed. Lean body mass was unchanged in both groups, despite weight loss. The overall safety profile of liraglutide was consistent with findings in previous reports. 19, 20 Interestingly, no changes in resting heart rate were detected in any of the groups, which is in contrast to previous studies with continuously acting GLP-1RAs, which reported a sustained increase in heart rate of approximately 2 to 4 beats/min. [19] [20] [21] Thus, further studies are warranted to elucidate whether exercise training is able to neutralize the well-known increase in heart rate seen with this class of glucose-lowering drugs.
An important limitation of the present study is the relatively small sample size of patients, reducing the power to detect subtle changes and increasing the risk of type II statistical errors. Despite this, we were able to demonstrate clinically relevant differences between the two groups. Another limitation of the study is the absence of diet records, which could have shown possible changes in diet after GLP-1RA treatment. Strengths of the study include the validated methods used; the study was performed as a single-centre, randomized, double-blind, placebo-controlled study, with only few physicians and experienced exercise physiologists involved (all the Abbreviations: DBP, diastolic blood pressure; FPG, fasting plasma glucose; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; SBP, systolic blood pressure; VO 2max , maximum oxygen uptake.
Data are mean AE standard deviation *P < .05, **P < .01 and ***P < .001 compared with baseline value within the group.
exercise sessions were performed under the supervision of the same two exercise physiologists). Supervised training was chosen because previous studies have shown improved results with supervision 22 and to support adherence to exercise training and exercise intensity. The period of 16 weeks was selected to allow sufficient time for uptitration of study drug (liraglutide and placebo) so that the maximum recommended dose could be maintained for a full 3-month period necessary for optimum evaluation of the primary endpoint (HbA1c) and, furthermore to ensure slow adaptation to exercise training to avoid injuries. A GLP-1RA as a glucose-lowering drug was selected because of the well-documented effect on glycaemic control and body weight in type 2 diabetes combined with a low risk of hypoglycaemia. 11 Only a limited number of previous trials with liraglutide have observed reductions in HbA1c up to 1.5% (in the majority of trials reductions ranged from 0.9% to 1.1%). 11 Pratley et al. 23 found
HbA1c reduction of 1.5% from baseline HbA1c levels of 8. 10 and in the brain, respectively. 26 Exercise training is known to increase insulin sensitivity of skeletal muscle in both healthy individuals and in patients with type 2 diabetes 27,28 and improves β-cell function in patients with type 2 diabetes with well-preserved residual β-cell function. 10 In individuals with impaired glucose tolerance and in patients with type 2 diabetes, β-cell function has been shown to be a better predictor of improvement in glycaemic control than insulin sensitivity. 29 Therefore, the beneficial effect of liraglutide on glycaemic control in the present exercise training study seems at least in part to be attributable to the insulinotropic effect of liraglutide, in line with the marked improvement in HOMA-β (Table 3) . Nevertheless, the substantial improvement in glycaemic control in the exercise plus liraglutide group, which markedly surpasses what previously has been observed with liraglutide in sedentary patients with type 2 diabetes, is probably attributable to the combination of improved β-cell function, as well as increased peripheral insulin sensitivity. In the exercise plus placebo group we assume that the lack of improvement in glycaemic control despite an expected increase in muscle insulin sensitivity 27, 29 may be attributable to inability of the residual β-cell reserve to benefit from increased insulin sensitivity. Glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body composition and maximum oxygen uptake (VO 2max ). A, HbA1c in exercise plus liraglutide (green at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). B, FPG in exercise plus liraglutide (green at baseline and green pattern), exercise plus placebo (blue at baseline and blue pattern at end of study). C, Differences in body weight in exercise plus liraglutide (green blue at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). D, Differences in fat mass in exercise plus liraglutide (green at baseline and blue pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). E, Estimated VO 2max in exercise plus liraglutide (green at baseline and green pattern at end of study), exercise plus placebo (blue at baseline and blue pattern at end of study). F, Proportions of patients archiving HbA1c targets after the intervention. Exercise plus liraglutide (green) exercise plus placebo (blue). Data are mean AE standard error of the mean. Significant differences (P < .05) between the groups are indicated by asterisks (*) and significant differences (P < .05) within the groups are indicated by hatch signs ( # ). anti-inflammatory effects. The pronounced effect on glycaemic control during the exercise plus liraglutide group, may to some extent, be explained by the well-known anti-inflammatory effects of both treatment methods. In larger and longer-lasting intervention studies, the effects on HbA1c might be less pronounced, as previously found in large-scale studies; for example, the LEAD 4 and 5 studies. 24, 25, 37 In the present study QoL was not further improved with liraglutide plus exercise despite improved glycaemic control compared with exercise alone. However, QoL was not inferior despite some side effects resulting from liraglutide treatment. These findings could indicate that exercise training is an essential factor for improvements in health-related QoL. Because adequate lifestyle changes are often difficult to implement and maintain in patients with type 2 diabetes, exercise in combination with liraglutide treatment may be a way to amplify motivation for change when the patients experience noticeable results from the effects of both exercise and liraglutide.
In conclusion, the combination of supervised exercise training and liraglutide induced major improvements in glycaemic control and may be an attractive treatment option for obese, dysregulated patients with type 2 diabetes on diet and/or metformin who are able to perform moderate-to high-intensity exercise training.
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